| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1.7 | — |
| Profit before tax | -18.9 | -20.3 |
| Net income | -18.9 | -20.3 |
| EPS (diluted, $ a share) | $-0.08 | $-0.12 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: TNYA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Tenaya Therapeutics, Inc.: key numbers
- Share price
- $0.3336Close, Nov 16
- Market cap
- $76M
- Shares outstanding
- 227.93MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Tenaya Therapeutics, Inc.
All →Tenaya Therapeutics Financial Results
Tenaya Therapeutics reported third quarter 2026 financial results, ending the period with $66.8 million in cash which provides a runway into Q4 2027. The company highlighted the recent FDA RMAT designation for its TN-401 gene therapy and expects to provide clinical data updates and pivotal trial planning feedback for both TN-201 and TN-401 by year-end.
“As we celebrate the tenth anniversary of Tenaya, we are entering one of the most important periods in the Company’s history. The forthcoming data updates from TN-201 and TN-401, together with regulatory feedback on potential pivotal development pathways, are expected to inform potential opportunities to advance these programs toward late-stage development.”
Faraz Ali, Chief Executive Officer of Tenaya